How to optimize HCV therapy in genotype 2 patients

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 35-40

  Grassi, Eleonora ^a   Aghemo, Alessio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cirrhosis; Directly acting antivirals; Hepatitis C; Il28B; RVR; Short duration treatment; SVR

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; SILIBININ; TELAPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; COST CONTROL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C; ALPHA2A; HEPATITIS C; ALPHA2B; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; PERSONALIZED MEDICINE; PREDICTIVE VALUE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; PATIENT SELECTION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SERINE PROTEINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872042189     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12056     Document Type: Review

References (47)

1. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31(Suppl. 2): 30-60.
2. Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008; 12: 239-44.
3. Young AM, Crosby RA, Oser CB, et al. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012; 84: 1376-87.
4. Oh DJ, Park YM, Seo YI, Lee JS, Lee JY. Prevalence of hepatitis C virus infections and distribution of hepatitis C virus genotypes among Korean blood donors. Ann Lab Med 2012; 32: 210-5.
5. Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 1127-34.
6. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-66.
7. De Nicola S, Aghemo A, Rumi MG, Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 964-6.
8. Rumi MG, De Filippi F, Donato MF, Del Ninno E, Colombo M. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 2002; 9: 71-4.
9. Rumi MG, De Filippi F, La Vecchia C, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402-6.
10. Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2012; 55: 634-41.
11. Torres HA, Nevah MI, Barnett BJ, et al. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. J Clin Virol 2012; 54: 218-22.
12. Rizzetto M. Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin. J Hepatol 2005; 42: 275-6.
13. Rumi MG, Aghemo A, D'Ambrosio R, et al. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Ther 2007; 12: 1033-40.
14. Shiffman ML, Suter F, Bacon BR, et al. ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
15. Aghemo A, Rumi MG, Monico S, et al. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir Ther 2009; 14: 577-84.
16. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-15.
17. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.
18. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
19. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012. doi: 10.1002/hep.25892.
20. Powis J, Peltekian KM, Lee SS, et al. Canadian Pegasys Study Group. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008; 15: 52-7.
21. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment- induced viral clearance. Nature 2009; 461: 399-401.
22. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-32.
23. De Nicola S, Aghemo A, Rumi MG, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55: 336-42.
24. Shi KQ, Liu WY, Lin XF, et al. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis. Gene 2012; 507: 27-35.
25. Sarrazin C, Susser S, Doehring A, et al. Importance of Il28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.
26. Mangia A, Thompson AJ, Santoro R, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7.
27. Prati GM, Aghemo A, Rumi MG, et al. Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol 2012; 56: 341-7.
28. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
29. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa- 2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
30. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
31. Dalgard O, Bjøro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-5.
32. von Wagner M, Huber M, Berg T, et al. Peginterferon alpha2a and ribavirin for 16 or 24 weeks in patients with genotype 2 and 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.
33. Di Martino V, Richou C, Cervoni JP, et al. Responseguided peg-interferon plus ribavirin treatment duration inchronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54: 789-800.
34. Ferenci P, Brunner H, Laferl H, et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008; 47: 1816-23.
35. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
36. Jacobson IM, Brown RS Jr, Freilich B, et al. WIN-R Study Group. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-81.
37. Mangia A, Mottola L. What's new in HCV genotype 2 treatment. Liver Int 2012; 32(Suppl. 1): 135-40.
38. Ghany MG, Nelson DR, Strader DB, Thomas DL, American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
39. Aghemo A, Degasperi E, Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Dig Liver Dis 2012. [Epub ahead of print] doi: 10.1016/j.dld.2012.05.002
40. Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-9.
41. Silva M, Kasserra C, Gupta S, et al. Antiviral activity of boceprevir monotherapy intreatment-naive subjects with chronic hepatitis C genotype 2/3. Hepatol Int 2011; 5: 259.
42. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56: 1019-24.
43. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-7.
44. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52: 951-2.
45. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol 2011; 54: 591-2.
46. Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2A liver graft reinfection. Hepat Mon 2012; 12: 411-4.
47. Wagoner J, Morishima C, Graf TN, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS ONE 2011; 6: e16464.